Skip to content

Alligator Bioscience

  •  
    • Se
  • Startpage
  • About Alligator
    • Board of Directors
    • Senior Management
    • Career
  • Research and development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • Neo-X-PrimeTM
      • ALG.APV-527
      • ATOR-1017
      • Research projects
    • Scientific publications
    • Technology platform
      • Alligator-GOLD®
      • Alligator-FABTM
      • FIND®
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination Committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and owner information
    • Sharegraph
    • Analysts
    • Preferential Rights Issue Q2 2023
    • Preferential Rights Issue Q4 2021
    • Preferential Rights Issue Q1 2021
    • IPO
    • Financial reports
      • Interim reports
      • Year End Reports
      • Annual reports
    • Financial calendar
    • Presentations
  • Business Development
  • News
  • Press releases
  • Contact
  • Events

  1. Startpage
  2. News
  3. ALG.APV-527
Key downloads
Bulletin from the annual general meeting in Alligator Bioscience AB on 26 May 2023Alligator Bioscience AB reports financial results for Q1 2023 and provides a business updateBulletin from the extraordinary general meeting in Alligator Bioscience ABAlligator Bioscience publishes Annual Report for 2022Alligator Bioscience AB reports full year financial results for 2022 and for Q4 2022 and provides a business update
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
All IRRegulatoryReport
View as grid View as list
2022-09-192022-09-19

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a “May Proceed” Notification for the ALG.APV-527 IND

Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor types. Lun ...
Continue reading
  1. Startpage
  2. News
  3. ALG.APV-527
About Alligator

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase 2 studies and beyond.

Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).

Links
  • About Alligator
  • R&D
  • Corporate governance
  • Investors
  • News
  • Business Development
  • Privacy Policy
Contact us

Headquarter
Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund Sweden

Satellite office
Alligator Bioscience AB
Forskaren
Scheelevägen 22
SE-223 63 Lund
Sweden

Phone:
+ 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com
bd@alligatorbioscience.com

Follow us

  

Email subscription

Subscribe to get our pressreleases and investor alerts by email from Alligator Bioscience.

Subscribe

  • © Copyright 2019 – Alligator Bioscience AB

  • Privacy Policy | Use of Cookies |  Change your cookie settings here.

  • Disclaimer Market data could be delayed. Delivered by Modular Finance.

Cookies
We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.
Settings Accept all
Cookies
Do your settings below. Or read our cookie policy.
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all